Bio-techne (TECH) Stock
Life science tools provider for research and diagnostics. Here's the price, business snapshot, and what's worth knowing about Bio-techne in August 2026.
Bio-Techne Corporation (TECH) supplies reagents, instruments and services used in life-science research, diagnostics and biopharma development. Investors should know it primarily sells consumables and specialised instruments to research organisations, pharmaceutical companies and clinical labs — a mix that can provide recurring revenue from consumables alongside more cyclical instrument sales. Growth has been driven by new product introductions, recurring demand for assays and reagents, and periodic acquisitions that expand capability and geographic reach. Key risks include sensitivity to research and R&D spending cycles, competitive pressure from other suppliers, supply-chain disruptions and regulatory or reimbursement shifts that can affect diagnostic adoption. The company’s market capitalisation is about $9.88bn, which positions it as a mid‑cap player in the life‑sciences tools space. This summary is educational, not investment advice: values can rise and fall and past performance is not a guarantee of future results. Review the latest financial reports and consider your own circumstances before deciding.
About This Stock
BIO-TECHNE CORP
TECH
Current Price
$72.47
Potential 12 Month Profit
-32.73%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
TECH
Market Cap
$11.29B
Potential 12 Month Profit
-32.73%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Bio-Techne's stock with a target price of $84.09, indicating growth potential.
Financial Health
BIO-TECHNE CORP is performing well with strong revenue, profit margins, and cash flow.
Dividend
BIO-TECHNE's low dividend yield of 0.45% indicates limited income potential for investors seeking dividends. If you invested $1000 you would be paid $4.50 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Research tools demand
Rising R&D spending and biotech activity can support steady demand for reagents and assays, though demand can fluctuate with research budgets.
Diversified customer base
Sales to academic, biotech, pharma and clinical labs can smooth revenue, but geographic and customer concentration risks remain.
M&A and innovation
Acquisitions and product launches can accelerate capability and growth, but integration and execution risks should be monitored.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.